An open label clinical study to evaluate the Safety, Tolerability andIn-use efficacy of HBWW-052005

Himalaya Wellness Company0 个研究点目标入组 84 人开始时间: 待定最近更新: 2023年5月29日

试验速览

暂无简介。

•1.Healthy subjects in the age group as below (inclusive of both genders).
•Group 1: >=18-<=45 years (both inclusive).
•Group 2: >= 2 - -<=12 years (both inclusive).
•Group 3: 0 months â?? -<=2 years (both inclusive).
•Group 4: Premature babies (babies born before 37 weeks).
•2.Healthy day 1 babies not requiring medical attention.
•3.Babies with signs of atopic dermatitis (dry skin, itchy skin, redness, sensitive skin, rashes) who does not require medical/ systemic treatment to be included. Included in group 2 (6 subjects) and group 3 (15 subjects) with signs of atopic dermatitis.
•4.Subjects in general good health as determined from a recent medical history.
•5.Subjects mother/legal representative, preferably mother willing to give a voluntary written informed consent and agree to come for regular follow up.
•6.Subjects mother/legal representative, preferably mother willing to abide by and comply with the study protocol.
•7.Subjects should not participate in any other clinical study during participation in the current study.

发起方